Megacolon in inflammatory bowel disease: response to infliximab
نویسندگان
چکیده
منابع مشابه
Management of inflammatory bowel disease in poor responders to infliximab
Infliximab (IFX) is an effective treatment for inducing and maintaining response in Crohn's disease and ulcerative colitis patients. Some patients present lack of response or loss of response to IFX during maintenance therapy. Empirical management with combination therapy with an immunomodulator, IFX dose escalation, or switching IFX for another antitumor necrosis factor-α drug, mainly adalimum...
متن کاملPyoderma gangrenosum associated with inflammatory bowel disease. Report of two cases with good response to infliximab.
Among the extraintestinal manifestations of inflammatory bowel disease (IBD), pyoderma gangrenosum (PG) often poses a therapeutic challenge. We describe two cases of PG associated with inflammatory bowel disease, who responded to treatment with Infliximab.
متن کاملPyoderma Gangrenosum Associated With Inflammatory Bowel Disease. Report of Two Cases With Good Response to Infliximab
Among the extraintestinal manifestations of inflammatory bowel disease (IBD), pyoderma gangrenosum (PG) often poses a therapeutic challenge. We describe two cases of PG associated with inflammatory bowel disease, who responded to treatment with Infliximab. © 2011 Elsevier España, S.L. All rights reserved. Pioderma gangrenoso asociado a enfermedad inflamatoria intestinal. Descripción de 2 casos ...
متن کاملPeripheral neuropathy with infliximab therapy in inflammatory bowel disease.
To the Editor: Antitumor necrosis factor alpha (antiTNF ) agents have provided an important breakthrough in the management of patients with inflammatory bowel disease (IBD), leading to high remission rates, fistula closure, and improved quality of life. However, they are not without serious adverse effects, including lymphoma, infection, bowel obstruction, and neuropathy.1 This case report illu...
متن کاملSafety of infliximab in patients suffering from inflammatory bowel disease.
Accessible online at: www.karger.com/dig Tumor necrosis factor-· (TNF-·) is a central cytokine in the inflammatory process associated with Crohn’s disease (CD). Infliximab, a chimeric IgG1 antibody directed against soluble and membrane-bound TNF-·, has shown efficacy both in luminal and fistulizing CD. It was approved in October 1998 by the US Food and Drug Administration for the treatment of m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Revista Española de Enfermedades Digestivas
سال: 2020
ISSN: 1130-0108
DOI: 10.17235/reed.2020.6394/2019